Cargando…
Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
BACKGROUND: Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are candidates for surgery at the time of diagnosis. Thus, there is a great global unmet need for valuable biomarkers that cou...
Autores principales: | Cao, Ying-Ying, Guo, Kai, Zhao, Rui, Li, Yuan, Lv, Xiao-Jing, Lu, Zi-Peng, Tian, Lei, Ren, Shuai, Wang, Zhong-Qiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259126/ https://www.ncbi.nlm.nih.gov/pubmed/37312938 http://dx.doi.org/10.1177/20552076231179007 |
Ejemplares similares
-
Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics
por: Martín-Blázquez, Ariadna, et al.
Publicado: (2020) -
Exploring the key genetic association between chronic pancreatitis and pancreatic ductal adenocarcinoma through integrated bioinformatics
por: Guo, Kai, et al.
Publicado: (2023) -
Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma
por: Ren, Shuai, et al.
Publicado: (2020) -
Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022) -
Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)